Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial

Stephan Fuhrmann, MD, Leonid Karawajew, Richard Schabath, Anja Moricke, MD, Martin Zimmermann, PhD, Wolf-Dieter Ludwig, Martin Schrappe, MD PhD, Richard Ratei

Blood (2016) 128 (22): 760.

https://doi.org/10.1182/blood.V128.22.760.760

Published: 2016

Journal Articles

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

Blood (2014) 124 (21): 131.

https://doi.org/10.1182/blood.V124.21.131.131

Published: 2014

Journal Articles

The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Eva Hoster, PhD, Michael Unterhalt, MD, Michael Pfreundschuh, Michael Hallek, MD, Roswitha Forstpointner, Bernd Metzner, Hermann Einsele, Jürgen Krauter, MD, Ulrich Dührsen, Wolf-Dieter Ludwig, Josef Birkmann, Norma Peter, Wolfram Klapper, MD, Martin H. Dreyling, Wolfgang Hiddemann, MD PhD

Blood (2014) 124 (21): 1752.

https://doi.org/10.1182/blood.V124.21.1752.1752

Published: 2014

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

Nicola Gökbuget, Michael Kneba, Thorsten Raff, Heiko Trautmann, Claus-Rainer Bartram, Renate Arnold, Rainer Fietkau, Mathias Freund, Arnold Ganser, Wolf-Dieter Ludwig, Georg Maschmeyer, Harald Rieder, Stefan Schwartz, Hubert Serve, Eckhard Thiel, Monika Brüggemann, Dieter Hoelzer

Blood (2012) 120 (9): 1868–1876.

https://doi.org/10.1182/blood-2011-09-377713

Published: 2012

Includes: Supplemental data

Journal Articles

Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment

Peter Rhein, PhD, Rita Mitlohner, Renate Kirschner-Schwabe, PhD, Christian Hagemeier, MD, PhD, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Schrappe, MD, Iduna Fichtner, PhD, Richard Ratei, MD, Wolf-Dieter Ludwig, Leonid Karawajew, PhD

Blood (2011) 118 (21): 752.

https://doi.org/10.1182/blood.V118.21.752.752

Published: 2011

Journal Articles

NOTCH1 Activation Neutralizes the Unfavorable Prognostic Effect of PTEN Mutations in BFM-Treated Children with T-ALL

Obul R Bandapalli, PhD, Corinne Kox, PhD, Martin Zimmermann, PhD, Martin Stanulla, MD, MSc, Martin Schrappe, MD, Wolf-Dieter Ludwig, Rolf Koehler, PhD, Martina U. Muckenthaler, PhD, Andreas E Kulozik, MD, PhD

Blood (2011) 118 (21): 740.

https://doi.org/10.1182/blood.V118.21.740.740

Published: 2011

Journal Articles

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

Nicola Goekbuget, MD, Daniel Stanze, MD, Renate Arnold, Monika Brueggemann, MD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Wolf-Dieter Ludwig, Georg Maschmeyer, MD, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Hubert Serve, MD, Michael Kneba, MD, Dieter Hoelzer, MD

Blood (2011) 118 (21): 250.

https://doi.org/10.1182/blood.V118.21.250.250

Published: 2011

Journal Articles

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Blood (2011) 118 (21): 2773.

https://doi.org/10.1182/blood.V118.21.2773.2773

Published: 2011

Journal Articles

High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients

Gunnar Cario, MD, Rita Mitlohner, Martin Zimmermann, PhD, Renja Romey, Peter Rhein, PhD, André Schrauder, MD, Anja Moericke, MD, Jean-Pierre Bourquin, MD, PhD, Wolf-Dieter Ludwig, MD, Richard Ratei, MD, Martin Schrappe, MD, Leonid Karawajew, PhD, Martin Stanulla, MD, MSc

Blood (2011) 118 (21): 742.

https://doi.org/10.1182/blood.V118.21.742.742

Published: 2011

Journal Articles

Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Eva Hoster, Dr., Michael Unterhalt, Dr., Bernd Metzner, Michael Pfreundschuh, MD, Peter Staib, Georg Jacobs, Hans Walter Lindemann, Wolf-Dieter Ludwig, H. Tilman Steinmetz, Lorenz Truemper, Hannes Wandt, Christian Buske, Martin H. Dreyling, PhD, Wolfgang Hiddemann, PhD

Blood (2011) 118 (21): 1639.

https://doi.org/10.1182/blood.V118.21.1639.1639

Published: 2011

Journal Articles

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification

Estella Matutes, Winfried F. Pickl, Mars van't Veer, Ricardo Morilla, John Swansbury, Herbert Strobl, Andishe Attarbaschi, Georg Hopfinger, Sue Ashley, Marie Christine Bene, Anna Porwit, Alberto Orfao, Petr Lemez, Richard Schabath, Wolf-Dieter Ludwig

Blood (2011) 117 (11): 3163–3171.

https://doi.org/10.1182/blood-2010-10-314682

Published: 2011

Journal Articles

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

Petra Breithaupt, PhD, Barbara Meissner, MD, Martin Zimmermann, Anja Möricke, MD, André Schrauder, MD, Jochen Harbott, Wolf-Dieter Ludwig, MD, PhD, Rolf Köhler, PhD, Claus R Bartram, MD, Martin Schrappe, MD, Gunnar Cario, MD, Martin Stanulla, MD, MSc

Blood (2010) 116 (21): 409.

https://doi.org/10.1182/blood.V116.21.409.409

Published: 2010

Journal Articles

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia

Peter Rhein, Rita Mitlohner, Giuseppe Basso, Giuseppe Gaipa, Michael N. Dworzak, Renate Kirschner-Schwabe, Christian Hagemeier, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Leonid Karawajew, Richard Ratei

Blood (2010) 115 (18): 3763–3771.

https://doi.org/10.1182/blood-2009-10-247585

Published: 2010

Journal Articles

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Blood (2010) 115 (16): 3206–3214.

https://doi.org/10.1182/blood-2009-10-248146

Published: 2010

Includes: Supplemental data

Journal Articles

Thiopurine Methyltransferase Genetics Is Associated with Treatment Outcome and Hepatic Toxicity in Pediatric Patients with Acute Lymphoblastic Leukemia: a Report From the ALL-BFM Study Group.

Martin Stanulla, MD, Elke Schäffeler, PhD, Silke Pohlschmidt, Martin Zimmermann, PhD, Anja Möricke, MD, Gunnar Cario, MD, Andre Schrauder, MD, Karl Welte, MD, Jochen Harbott, PhD, Wolf-Dieter Ludwig, MD, Alfred Reiter, MD, Michel Eichelbaum, MD, Martin Schrappe, MD, Matthias Schwab, MD

Blood (2009) 114 (22): 2625.

https://doi.org/10.1182/blood.V114.22.2625.2625

Published: 2009

Journal Articles

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

Nicola Goekbuget, MD, Monika Brueggemann, MD, Renate Arnold, MD, Claus-Rainer Bartram, PhD, Rainer Fietkau, MD, Mathias Freund, MD, Arnold Ganser, MD, Michael Kneba, MD, PhD, Thomas Lipp, MD, Wolf-Dieter Ludwig, MD, Georg Maschmeyer, MD, Dorle Messerer, Thorsten Raff, MD, Harald Rieder, MD, Eckhard Thiel, Dieter Hoelzer, MD, PhD

Blood (2009) 114 (22): 90.

https://doi.org/10.1182/blood.V114.22.90.90

Published: 2009

Journal Articles

The Favorable Effect of Activating NOTCH1 Receptor Mutations On Long Term Outcome in T-ALL Is Treatment Related and Can Be Separated From NOTCH Pathway Activation by FBXW7 Loss of Function.

Corinne Kox, Martin Zimmermann, PhD, Martin Stanulla, MD, Martin Schrappe, MD, Wolf-Dieter Ludwig, Rolf Koehler, PhD, Svenja Leible, Gabriele Tolle, Obul Reddy Bandapalli, Stephen Breit, Martina Ulrike Muckenthaler, Andreas Kulozik, MD, PhD

Blood (2009) 114 (22): 908.

https://doi.org/10.1182/blood.V114.22.908.908

Published: 2009

Journal Articles

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Blood (2009) 114 (22): 485.

https://doi.org/10.1182/blood.V114.22.485.485

Published: 2009

Journal Articles

High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-β and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response

Blood (2009) 114 (5): 1053–1062.

https://doi.org/10.1182/blood-2008-10-186536

Published: 2009

Includes: Supplemental data

NARROW

T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment

NOTCH1 Activation Neutralizes the Unfavorable Prognostic Effect of PTEN Mutations in BFM-Treated Children with T-ALL

Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients

Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Thiopurine Methyltransferase Genetics Is Associated with Treatment Outcome and Hepatic Toxicity in Pediatric Patients with Acute Lymphoblastic Leukemia: a Report From the ALL-BFM Study Group.

New Definition of Treatment Response in Adult Acute Lymphoblastic Leukemia (ALL): Use of Molecular Markers for Minimal Residual Disease (MRD).

The Favorable Effect of Activating NOTCH1 Receptor Mutations On Long Term Outcome in T-ALL Is Treatment Related and Can Be Separated From NOTCH Pathway Activation by FBXW7 Loss of Function.

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-β and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only